System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ahead of print

PubMed: 42829087 DOI: 10.1016/j.jtha.2026.09.035

Thrombotic rates in individuals with inherited bleeding disorders treated with concentrate or bispecific antibody. Fifteen-year EUHASS data.

J Thromb Haemost

Authors: M Makris, K Fischer, A Gatt, S Gouw, R Hollingsworth, N Kabera, R Kaczmarek, T Lambert, R Lassila, F Peyvandi

Affiliations

  • School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
  • Center for Benign Haematology, Van Creveldkliniek, University Medical Centre Utrecht, University of Utrecht, the Netherlands.
  • Mater Dei Hospital, Tal-Qroqq, Msida, Malta.
  • Department of Pediatric Hematology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Reproduction & Development, Public Health, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Medical Data Solutions and Services, Manchester, UK.
  • EAHAD, Brussels, Belgium.
  • Wells Centre for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Reference Centre for Hemophilia and Rare Bleeding Disorders, Hopital Bicetre, APHP, Universite Paris Saclay, Le Kremlin Bicetre, France.
  • Coagulation Disorders Unit, Division of Hematology, Department of Medicine, Helsinki University Central Hospital, and Research Program unit in Systems Oncology, University of Helsinki, Finland.
  • Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Fondazione Instituto, Candiolo Centro Oncologico d'Eccelenza, Ca' Granda Ospidale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

Abstract

BACKGROUND

Although inherited bleeding disorders are associated with a reduced risk of thrombosis, the rate of thrombosis following treatment of the bleeding disorders is unknown.

OBJECTIVE

To determine the rates of thrombosis in persons with inherited bleeding disorders treated with clotting factor concentrates or a bispecific antibody.

METHODS

Analysis of the thrombotic events reported to the EUHASS system. EUHASS is the European surveillance system for adverse events in persons with all inherited bleeding disorders treated with clotting factor concentrates and/or emicizumab. 95 sentinel centres from 27 countries participated. From 10/2008 to 12/2023, thrombotic events occurring within 30 days of product administration, and the number of persons treated with each product were reported. Annual thrombosis rates (95% confidence intervals-CI) according to the product were compared using rate ratios.

RESULTS

During the 15-year period, 204 episodes of thrombosis occurred in 209,842 treatment years 113 events were in hemophilia A, 22 in hemophilia B, 22 in von Willebrand disease, and 47 in other bleeding disorders. The rates of thrombosis following plasma-derived FVIII was 1.10, recombinant standard half-life FVIII 0.70 and extended half-life FVIII 0.52 per 1000 patient years. The rate for emicizumab (Hemlibra) was 0.92 per 1000 patient years. The highest rate was in persons treated with fibrinogen concentrate at 11.56 per 1000 patient years.

CONCLUSION

The rate of thrombosis in persons with hemophilia A and B treated with FVIII and IX concentrates, respectively, is less than 1.0 per 1000 patient years. This information can be used in comparisons with rates for newly introduced products.

MeSH

Hemorrhage, Hemophilia A, Blood Coagulation Factors, Therapeutics, Thrombosis